Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (300760.SZ)
Shenzhen, CN
Operating on a global scale, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. specializes in providing a comprehensive range of medical devices and innovative healthcare solutions. Its extensive portfolio encompasses several key segments. Within patient monitoring and life support, the company manufactures crucial equipment such as patient monitoring systems, electrocardiographs, defibrillators, anesthesia machines, ventilators, infusion pumps, surgical lights, operating tables, medical supply units, and endoscopes, along with associated accessories. This segment also delivers integrated solutions for emergency care, peri-operative management, critical care, and medical IT systems. For in-vitro diagnostics, Mindray offers sophisticated products including hematology and chemistry analyzers and their reagents, chemiluminescence immunoassay products, hemoglobin systems, flow cytometry instruments, and microplate readers and washers. These are further supported by solutions tailored for coagulation, urinalysis, and microbiology. The company additionally produces advanced medical imaging systems, covering both ultrasound and radiology products, and supplies a dedicated line of veterinary products. Founded in 1991, Shenzhen Mindray Bio-Medical Electronics Co., Ltd. maintains its primary operational base in Shenzhen, People's Republic of China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.67% | -3.93% | +5.19% | -11.49% | -20.08% | -12.63% | -27.39% | -45.76% | -63.10% | +136.79% | +136.79% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 4 | 0 |
| Buy | 20 | -2 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Devices: +11.2%-9.4% Q1'26: +1.4% (vs Q1'25)
-
EPS growth Medical - Devices: +28.5%-30.3% Q1'26: -11.5% (vs Q1'25)
-
FCF margin FCF growth · Medical - Devices: +30.9%+22.9% Q1'26: +9.3% (vs Q1'25)
-
EBIT margin Medical - Devices: +6.2%+27.9% ★ Q1'26: +33.4% (vs Q1'25)
-
ROIC Medical - Devices: +3.3%+32.1% ★ Q1'26: +39.3% (vs Q1'25)
-
Share dilution Medical - Devices: 0.0%+0.1% Q1'26: +0.0% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×0.02× ★ Q1'26: 0.03× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 21 Rev. Ana. 12 EPS Ana. |
Dec 2027 24 Rev. Ana. 15 EPS Ana. |
Dec 2028 18 Rev. Ana. 17 EPS Ana. |
Dec 2029 11 Rev. Ana. 13 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
13.75B
est: 13.75B (+0.0%)
|
16.56B
est: 16.60B (-0.2%)
|
21.03B
est: 21.15B (-0.6%)
|
25.27B
est: 25.52B (-1.0%)
|
30.37B
est: 30.53B (-0.5%)
|
34.93B
est: 36.99B (-5.6%)
|
36.73B
est: 37.21B (-1.3%)
|
33.28B
est: 34.14B (-2.5%)
|
35.69B
34.36B – 38.35B
+4.6% YoY
|
39.30B
35.10B – 43.84B
+10.1% YoY
|
43.45B
43.20B – 43.69B
+10.5% YoY
|
50.14B
46.43B – 54.96B
+15.4% YoY
|
| EBITDA |
4.38B
est: 5.10B (-14.2%)
|
5.39B
est: 6.16B (-12.6%)
|
7.73B
est: 7.85B (-1.6%)
|
9.38B
est: 9.48B (-1.0%)
|
11.19B
est: 11.34B (-1.3%)
|
13.16B
est: 13.43B (-2.0%)
|
13.69B
est: 13.51B (+1.3%)
|
10.85B
est: 12.39B (-12.4%)
|
12.96B
12.47B – 13.92B
+4.6% YoY
|
14.27B
12.74B – 15.92B
+10.1% YoY
|
15.77B
15.68B – 15.86B
+10.5% YoY
|
18.20B
16.85B – 19.95B
+15.4% YoY
|
| EBIT |
4.05B
est: 4.74B (-14.5%)
|
4.99B
est: 5.72B (-12.7%)
|
7.26B
est: 7.29B (-0.4%)
|
8.76B
est: 8.79B (-0.3%)
|
10.41B
est: 10.52B (-1.0%)
|
12.26B
est: 12.26B (+0.0%)
|
12.37B
est: 12.33B (+0.3%)
|
9.30B
est: 11.31B (-17.8%)
|
11.83B
11.39B – 12.71B
+4.6% YoY
|
13.02B
11.63B – 14.53B
+10.1% YoY
|
14.40B
14.32B – 14.48B
+10.5% YoY
|
16.62B
15.39B – 18.21B
+15.4% YoY
|
| Net Income |
3.72B
est: 3.75B (-0.8%)
|
4.68B
est: 4.65B (+0.7%)
|
6.66B
est: 6.41B (+3.8%)
|
8.00B
est: 8.19B (-2.3%)
|
9.61B
est: 9.70B (-0.9%)
|
11.58B
est: 12.70B (-8.8%)
|
11.67B
est: 12.50B (-6.6%)
|
8.14B
est: 9.91B (-17.9%)
|
8.61B
7.91B – 9.37B
-13.1% YoY
|
10.22B
7.90B – 12.22B
+18.7% YoY
|
10.95B
9.57B – 14.21B
+7.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
3.92B
est: 2.73B (+43.6%)
|
4.37B
est: 3.29B (+32.7%)
|
4.51B
est: 4.20B (+7.4%)
|
5.10B
est: 5.06B (+0.8%)
|
6.12B
est: 6.06B (+1.0%)
|
6.53B
est: 7.24B (-9.8%)
|
6.88B
est: 7.29B (-5.6%)
|
6.70B
est: 6.69B (+0.1%)
|
6.99B
6.73B – 7.51B
+4.6% YoY
|
7.70B
6.87B – 8.59B
+10.1% YoY
|
8.51B
8.46B – 8.56B
+10.5% YoY
|
9.82B
9.09B – 10.76B
+15.4% YoY
|
| EPS |
3.34
est: 3.09 (+7.9%)
|
3.85
est: 3.84 (+0.3%)
|
5.48
est: 5.29 (+3.5%)
|
6.59
est: 6.76 (-2.5%)
|
7.94
est: 8.01 (-0.8%)
|
9.56
est: 10.48 (-8.8%)
|
9.64
est: 10.17 (-5.2%)
|
6.71
est: 8.06 (-16.8%)
|
7.31
6.53 – 7.73
-9.3% YoY
|
8.26
6.52 – 10.09
+12.9% YoY
|
8.91
7.90 – 11.72
+7.9% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-11 | A | 4/5 | 4/5 | 5/5 | 5/5 | 4/5 | 2/5 | 2/5 |
| 2026-05-08 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-07 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-05-06 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-30 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-29 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 2/5 |
| 2026-04-28 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-27 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-24 | A- | 4/5 | 4/5 | 5/5 | 5/5 | 3/5 | 2/5 | 1/5 |
| 2026-04-23 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-22 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-21 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-20 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-17 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-16 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-15 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
| 2026-04-14 | B+ | 3/5 | 4/5 | 5/5 | 5/5 | 2/5 | 2/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hao Wu | MD & Director | — | male |
| Jian Cen | Deputy General Manager | — | male |
| Laiping Liu | Deputy General Manager | — | male |
| Wei Wang | Chief Scientist | — | male |
| Wenzhao Li | Secretary of the board | — | female |
| Xinsheng Li | Senior Vice President | — | male |
| Yanmei Guo | Executive Deputy GM & Director | — | female |
| Yun Zhao | Head of Finance, Financial Manager & Accounting Supervisor | — | female |
| Zaiwen Li | Senior Vice President | — | male |
| Zhao Yang Li | Deputy General Manager | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 300760.SZ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
